Nature Communications (Apr 2021)

PAX8 and MECOM are interaction partners driving ovarian cancer

  • Melusine Bleu,
  • Fanny Mermet-Meillon,
  • Verena Apfel,
  • Louise Barys,
  • Laura Holzer,
  • Marianne Bachmann Salvy,
  • Rui Lopes,
  • Inês Amorim Monteiro Barbosa,
  • Cecile Delmas,
  • Alexandra Hinniger,
  • Suzanne Chau,
  • Markus Kaufmann,
  • Simon Haenni,
  • Karolin Berneiser,
  • Maria Wahle,
  • Ivana Moravec,
  • Alexandra Vissières,
  • Tania Poetsch,
  • Erik Ahrné,
  • Nathalie Carte,
  • Johannes Voshol,
  • Elisabeth Bechter,
  • Jacques Hamon,
  • Marco Meyerhofer,
  • Dirk Erdmann,
  • Matteo Fischer,
  • Therese Stachyra,
  • Felix Freuler,
  • Sascha Gutmann,
  • César Fernández,
  • Tobias Schmelzle,
  • Ulrike Naumann,
  • Guglielmo Roma,
  • Kate Lawrenson,
  • Cristina Nieto-Oberhuber,
  • Amanda Cobos-Correa,
  • Stephane Ferretti,
  • Dirk Schübeler,
  • Giorgio Giacomo Galli

DOI
https://doi.org/10.1038/s41467-021-22708-w
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Lineage-restricted transcription factor PAX8 is oncogenic in ovarian cancer cells. Here the authors show that PAX8 interacts and recruits a splice variant of the MECOM locus PRDM3 to control the gene expression module involved in adhesion and extracellular matrix, and consequently promotes ovarian tumorigenesis.